Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Long-Term Debt Repayments (2016 - 2017)

Corcept Therapeutics' Long-Term Debt Repayments history spans 2 years, with the latest figure at $4.6 million for Q3 2017.

  • For Q3 2017, Long-Term Debt Repayments rose 14.3% year-over-year to $4.6 million; the TTM value through Jun 2018 reached $4.6 million, down 75.71%, while the annual FY2017 figure was $15.1 million, 2.4% up from the prior year.
  • Long-Term Debt Repayments for Q3 2017 was $4.6 million at Corcept Therapeutics, down from $5.7 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $5.7 million in Q2 2017 and bottomed at $3.0 million in Q1 2016.